Normal immunoglobulin G protects against experimental allergic encephalomyelitis by inducing transferable T cell unresponsiveness to myelin basic protein

European Journal of Immunology

Volumn 28, Issue 6, 1998, Pages 1823-1831

  Pashov, Anastas ^a   Dubey, Caroline ^a   Kaveri, Srinivas V ^a   Lectard, Bruno ^a   Huang, Yi Ming ^a   Kazatchkine, Michel D ^a   Bellon, Blanche ^a,b  

^a INSERM   (France)

^b HÔPITAL BROUSSAIS   (France)

Author keywords

Anergy; Experimental allergic encephalomyelitis; Rat; Th1; Th2

Indexed keywords

GAMMA INTERFERON; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNE DISEASE; IMMUNIZATION; IMMUNOMODULATION; LYMPH NODE; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; T LYMPHOCYTE;

ANIMALS; CELLS, CULTURED; CLONAL ANERGY; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LYMPH NODES; MYELIN BASIC PROTEINS; RATS; RATS, INBRED LEW; T-LYMPHOCYTES;

EID: 0031867533     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1521-4141(199806)28:06<1823::AID-IMMU1823>3.0.CO;2-F     Document Type: Article

References (41)

1. Allegretta, M., Nicklas, J. A., Sriram, S. and Albertini, R. J., T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990. 247: 718-721.
2. Zamvil, S. S. and Steinman, L., The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 1990. 8: 579-621.
3. Sobel, R. A., Tuohy, V. K., Lu, Z. J., Laursen, R. A. and Lees, M. B., Acute experimental allergic encephalomyelitis in SJL/J mice induced by a synthetic peptide of myelin proteolipid protein. J. Neuropathol. Exp. Neurol. 1990. 49: 469-479.
4. Wekerle, H., Experimental autoimmune encephalomyelitis as a model of immune-mediated CNS disease. Curr. Opin. Neurobiol. 1993. 3: 779-784.
5. Kerlero de Rosbo, N., Mendel, I. and Ben-Nun, A., Chronic relapsing experimental autoimmune encephalomyelitis with a delayed onset and an atypical clinical course, induced in PL/J mice by myelin oligodendrocyte glycoprotein (MOG)-derived peptide: preliminary analysis of MOG T cell epitopes. Eur. J. Immunol. 1995. 25: 985-993.
6. Kuchroo, V. K. Martin, C. A., Greer, J. M., Ju, S., Sobel, R. A. and Dorf, M. E., Cytokines and adhesion molecules contribute to the ability of myelin proteolipid protein-specific T cell clones to mediate experimental allergic encephalomyelitis. J. Immunol. 1993. 151: 4371-4382.
7. Baron, J. L., Madri, J. A., Ruddle, N. H., Hashim, G. and Janeway, C. A., Jr., Surface expression of alpha 4 integrin by CD4 T cells in required for their entry into brain parenchyma. J. Exp. Med. 1993. 177: 57-68.
8. Dwyer, J. M., Manipulation the immune system with immune globulin. N. Engl. J. Med. 1992. 326: 107-116.
9. Kaveri, S. V., Dietrich, G., Hurez, V. and Kazatchkine, M. D., Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases [published erratum appears in Clin Exp Immunol 1992 May; 88(2):373]. Clin. Exp. Immunol. 1991. 86: 192-198.
10. Imbach, P., Barandun, S., d'Apuzzo, V., Baumgartner, C., Hirt, A., Morell, A., Rossi, E., Schoni, M., Vest, M. and Wagner, H. P., High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981. 1: 1228-1231.
11. Vermeulen, M. van der Meche, F. G., Speelman, J. D., Weber, A. and Busch, H. F., Plasma and gammaglobulin infusion in chronic inflammatory polyneuropathy. J. Neurol. Sci. 1985. 70: 317-326.
12. Furusho, K., Kamiya, T., Nakano, H. et al., High-dose intravenous gammaglobulin for Kawasaki disease. Lancet 1984. 2: 1055-1058.
13. Fehr, J., Hofmann, V. and Kappeler, U., Transient reversal of thrombocytopenia in idiopathic thrombocytopenic purpura by high-dose intravenous gamma globulin. N. Engl. J. Med. 1982. 306: 1254-1258.
14. Dietrich, G., Kaveri, S. V. and Kazatchkine, M. D., Modulation of autoimmunity by intravenous immune globulin through interaction with the function of the immune/idiotypic network. Clin. Immunol. Immunopathol. 1992. 62: 573-81.
15. Achiron, A., Gilad, R., Margalit, R. Gabbay, U., Sarova-Pinhas, I., Cohen, I. R., Melamed, E., Lider, O., Noy, S. and Ziv, I., Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. J. Neurol. Neurosurg. Psychiatry 1994. 57: 57-61.
16. Rossi, F., Bellon, B., Vial, M. C., Druet, P. and Kazatchkine, M. D., Beneficial effect of human therapeutic intravenous immunoglobulins (IVIg) in mercuric-chloride-induced autoimmune disease of Brown-Norway rats. Clin. Exp. Immunol. 1991. 84: 129-133.
17. Saoudi, A., Hurez, V., de Kozak, Y., Kuhn, J., Kaveri, S. V., Kazatchkine, M. D., Druet, P. and Bellon, B., Human immunoglobulin preparations for intravenous use prevent experimental autoimmune uveoretinitis. Int. Immunol. 1993. 5: 1559-1567.
18. Andersson, A., Forsgren, S., Soderstrom, A. and Holmberg, D., Monoclonal natural antibodies prevent development of diabetes in the non-obese diabetic (NOD) mouse. J. Autoimmunity 1991. 4: 733-742.
19. Amran, D., Renz, H., Lack, G., Bradley, K. and Gelfand, E. W., Suppression of cytokine-dependent human T-cell proliferation by intravenous immunoglobulin. Clin. Immunol. Immunopathol. 1994. 73: 180-186.
20. Andersson, U., Bjork, L., Skansen-Saphir, U. and Andersson, J., Pooled human IgG modulates cytokine production in lymphocytes and monocytes. Immunol. Rev. 1994. 139: 21-42.
21. Andersson, U. G., Bjork, L. Skansen-Saphir, U. and Andersson, J. P., Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology 1993. 79: 211-216.
22. Toyoda, M., Zhang, X., Petrosian, A., Galera, O. A., Wang, S. J. and Jordan, S. C., Modulation of immunoglobulin production and cytokine mRNA expression in peripheral blood mononuclear cells by intravenous immunoglobulin. J. Clin. Immunol. 1994. 14: 178-189.
23. Hurez, V., Kaveri, S. V., Mouhoub, A., Dietrich, G., Mani, J. C., Klatzmann, D. and Kazatchkine, M. D., Anti-CD4 activity of normal human immunoglobulins G for therapeutic use (Intravenous immunoglobulin, IVIg). Therap. Immunol. 1994. 1: 269-278.
24. Vassilev, T., Gelin, C., Kaveri, S. V., Zilber, M. T., Boumsell, L. and Kazatchkine, M. D., Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin. Exp. Immunol. 1993. 92: 369-372.
25. Kaveri, S., Vassilev, T., Hurez, V. Lengagne, R., Lefranc, D., Cot, S., Pouletty, P., Glotz, D. and Kazatchkine, M. D., Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function are present in pooled normal immunoglobulin for therapeutic use (IVIg). J. Clin. Invest. 1996. 97: 865-869.
26. Marchalonis, J. J., Kaymaz, H., Dedouglu, F., Schlutter, S. F., Yocum, D. and Edmundson, A. B., Human autoantibodies reactive with synthetic autoantigen from T-cell receptor β chain. Proc. Natl. Acad. Sci. USA 1992. 89: 3325-3329.
27. Rossi, F. and Kazatchkine, M. D., Antiidiotypes against autoantibodies in pooled normal human polyspecific Ig. J. Immunol. 1989. 143: 4104-4109.
28. Kaveri, S. V., Kang, C. Y. and Kohler, H., Natural mouse and human antibodies bind to a peptide derived from a germline variable heavy chain: Evidence for evolutionary conserved self-binding locus. J. Immunol. 1990. 145: 4207-4213.
29. + T cells and myelin basic protein-primed B cells. J. Neuroimmunol. 1991. 33: 173-177.
30. Achiron, A., Margalit, R., Hershkoviz, R., Markovits, D., Reshef, T., Melamed, E., Cohen, I. R. and Lider, O., Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis-factor alpha secretion. J. Clin. Invest. 1994. 93: 600-605.
31. Hutchings, P. R., Cooke, A., Dawe, K., Waldmann, H. and Roitt, I. M., Active suppression induced by anti-CD4. Eur. J. Immunol. 1993. 23: 965-968.
32. Pashov, A., Bellon, B., Kaveri, S. and Kazatchkine, M. D., A shift in encephalitogenic T cell cytokine pattern is associated with suppression of EAE by intravenous immunoglobulins (IVIg), in Allen, I. V. (Ed.) Conference on "Remyelination in Multiple Sclerosis-prospects for clinical treatments, gammaglobulins, transplantation". Stockton Press, Vienna, Austria 1997, vol.3, pp 153-156.
33. Lenschow, D. J., Walunas, T. L. and Bluestone, J. A., CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 1996. 14: 233-258.
34. Yssel, H., Fasler, S., Lamb, J. and de Vries, J. E., Induction of non-responsiveness in human allergen-specific type 2 T helper cells. Curr. Opin. Immunol. 1994. 6: 847-852.
35. Cobbold, S. P., Adams, E., Marshall, S. E., Davies, J. D. and Waldmann, H., Mechanisms of peripheral tolerance and suppression induced by monoclonal antibodies to CD4 and CD8. Immunol. Rev. 1996. 149: 5-33.
36. Brand, A., Vuist, W. M., Van Schaik, I. N. and Vermeulen, M., In vitro investigation of immunoglobulin treatment mechansism in autoimmuno diseases. Clin. Exp. Rheumatol. 1996. 14: 27-30.
37. Forsgren, S., Andersson, A., Hillorn, V., Soderstrom, A. and Holmberg, D., Immunoglobulin-mediated prevention of autoimmune diabetes in the non-obese diabetic (NOD) mouse. Scand. J. Immunol. 1991. 34: 445-451.
38. Eylar, E. H., Kniskern, P. J. and Jackson, J. J., Myelin basic proteins. Methods Enzymol. 1974. 32: 323-341.
39. Ferran, C., Sheehan, K., Dy, M. et al., Cytokine-related syndrome following injection of anti-CD3 monoclonal antibody: further evidence for transient in vivo T cell activation. Eur. J. Immunol. 1990. 20: 509-515.
40. Gillespie, K. M., Saoudi, A., Kuhn, J., Whittle, C. J., Druet, P., Bellon, B. and Mathieson, P., Th1/Th2 cytokine gene expression after mercuric chloride in susceptible and resistant rat strains. Eur. J. Immunol. 1996. 26: 2388-2392.
41. Nicoletti, A. and Sassy-Prigent, C., An alternative quantitative polymerase chain reaction method. Anal. Biochem. 1996. 236: 229-241.